Vicore Pharma (VICO) Investor presentation summary

Strategic vision and financial position

• Aims to transform patient outcomes by targeting the AT2 receptor to halt and reverse disease pathology.

• Operates from Stockholm, Cambridge, and Copenhagen, with a $303M market cap and $127M in financial reserves as of early 2026.

• Publicly listed on Nasdaq Stockholm and backed by leading US and European investors.

Lead program and clinical pipeline

• Lead asset buloxibutid is a first-in-class oral AT2 receptor agonist for IPF, with Orphan Drug and Fast Track FDA designations.

• Currently in a global Phase 2b trial (ASPIRE) targeting full enrollment by H1 2026.

• Holds global rights except for Japan, where partnered with Nippon Shinyaku.

Market opportunity and unmet need

• IPF is a fatal, progressive disease with high unmet need; current therapies offer only modest benefit and poor tolerability.

• Global IPF market projected to grow from $4.2B in 2024 to over $10B by 2030-33, driven by new approvals and rising diagnosis rates.